

Sexual Medicine

Open Access



REVIEW

Behavioral Therapies for Management of Premature Ejaculation: A Systematic Review

Katy Cooper, PhD,* Marrison Martyn-St James, PhD,* Eva Kaltenthaler, PhD,* Kath Dickinson, MA,* Anna Cantrell, MA,* Kevan Wylie, FRCP, FRCPSych, FECSM,[†] Leila Frodsham, MBChB, MRCOG,[‡] and Catherine Hood, BMBCh[§]

*University of Sheffield, Sheffield, UK; [†]Porterbrook Clinic, Sheffield, UK; [‡]Institute of Psychosexual Medicine, London, UK; [§]Imperial College, London, UK

DOI: 10.1002/sm2.65

ABSTRACT

Introduction. Premature ejaculation (PE) is defined by short ejaculatory latency and inability to delay ejaculation causing distress. Management may involve behavioral and/or pharmacological approaches.

Aim. To systematically review the randomized controlled trial (RCT) evidence for behavioral therapies in the management of PE.

Methods. Nine databases including MEDLINE were searched up to August 2014. Included RCTs compared behavioral therapy against waitlist control or another therapy, or behavioral plus drug therapy against drug treatment alone. [Correction added on 10 September 2015, after first online publication: Search period has been amended from August 2013 to August 2014.]

Main Outcome Measure. Intravaginal ejaculatory latency time (IELT), sexual satisfaction, ejaculatory control, and anxiety and adverse effects.

Results. Ten RCTs (521 participants) were included. Overall risk of bias was unclear. All studies assessed physical techniques, including squeeze and stop-start, sensate focus, stimulation device, and pelvic floor rehabilitation. Only one RCT included a psychotherapeutic approach (combined with stop-start and drug treatment). Four trials compared behavioral therapies against waitlist control, of which two (involving squeeze, stop-start, and sensate focus) reported IELT differences of 7–9 minutes, whereas two (web-based sensate focus, stimulation device) reported no difference in ejaculatory latency posttreatment. For other outcomes (sexual satisfaction, desire, and self-confidence), some waitlist comparisons significantly favored behavioral therapy, whereas others were not significant. Three trials favored combined behavioral and drug treatment over drug treatment alone, with small but significant differences in IELT (0.5–1 minute) and significantly better results on other outcomes (sexual satisfaction, ejaculatory control, and anxiety). Direct comparisons of behavioral therapy vs. drug treatment gave mixed results, mostly either favoring drug treatment or showing no significant difference. No adverse effects were reported, though safety data were limited.

Conclusions. There is limited evidence that physical behavioral techniques for PE improve IELT and other outcomes over waitlist and that behavioral therapies combined with drug treatments give better outcomes than drug treatments alone. Further RCTs are required to assess psychotherapeutic approaches to PE. **Cooper K, Martyn-St James M, Kaltenthaler E, Dickinson K, Cantrell A, Wylie K, Frodsham L, and Hood C. Behavioral therapies for management of premature ejaculation: A systematic review. Sex Med 2015;3:174–188.**

Key Words. Review; Systematic; Premature Ejaculation; Behavior Therapy; Psychological Therapy

Introduction

Premature ejaculation (PE) is a male sexual dysfunction characterized by short ejaculatory latency. PE can be either lifelong (primary, present since first sexual experiences) or acquired (secondary, beginning later). The 2014 update of the International Society for Sexual Medicine (ISSM) Guidelines for the Diagnosis and Treatment of Premature Ejaculation define PE as a combination of (i) ejaculation usually occurring within about 1 minute of vaginal penetration (for lifelong PE) or a clinically significant reduction in latency time, often to around 3 minutes or less (for acquired PE); (ii) inability to delay ejaculation; and (iii) negative personal consequences such as distress, bother, frustration, and/or the avoidance of sexual intimacy [1]. PE is similarly defined by Diagnostic and Statistical Manual of Mental Disorders 5 (DSM 5) (2013) as ejaculation usually occurring within about 1 minute of vaginal penetration and before the individual wishes it and causing clinically significant distress [1]. Estimating the prevalence of PE is not straightforward due to the difficulty in defining what constitutes clinically relevant PE. Surveys have estimated the prevalence of Diagnostic and Statistical Manual of Mental Disorders IV-defined PE as 20–30% [2–4]; however, these estimates are likely to include men who have some concern about their ejaculatory function but do not meet the current diagnostic criteria for PE [1]. It has been suggested that the prevalence of lifelong PE according to the ISSM and DSM-5 definitions (with an ejaculatory latency of about 1 minute) is unlikely to exceed 4% [1]. Men with PE are more likely to report lower levels of sexual functioning and satisfaction, and higher levels of personal distress and interpersonal difficulty, than men without PE [5]. They may also rate their overall quality of life as lower than that of men without PE [5]. In addition, their partner's satisfaction with the sexual relationship has been reported to decrease with increasing severity of the condition [6]. Management of PE may involve a range of interventions. These include systemic drug treatments (such as selective serotonin reuptake inhibitors, tricyclic antidepressants, phosphodiesterase type 5 inhibitors, and analgesics), topical anesthetic creams and sprays, and behavioral therapies (BTs) [7,8].

Behavioral and psychological therapies for PE include two main classes of therapy, with overlapping elements [1]. The first consists of psychotherapy (such as psychosexual or relationship

counselling) for men and/or couples, to address psychological and interpersonal issues that may be contributing to PE. The second consists of physical techniques to help men develop sexual skills to delay ejaculation and improve sexual self-confidence. Specific physical techniques include the following. The “stop-start” technique, developed by Semans, involves the man or his partner stimulating the penis until he feels the urge to ejaculate, then stopping until the sensation passes; this is repeated a few times before allowing ejaculation to occur [9]. The aim is to learn to recognize the feelings of arousal in order to improve control over ejaculation. With the related “squeeze” technique, proposed by Masters and Johnson, the man's partner stimulates the penis until he feels the urge to ejaculate, then squeezes the glans of the penis until the sensation passes; this is repeated before allowing ejaculation to occur [9]. Within sensate focus or sensate focusing [7], the man and his partner begin by focusing on touch, which excludes breasts, genitals, and intercourse, to encourage body awareness while reducing performance anxiety; this is followed by gradual reintroduction of genital touching and then full intercourse [10]. Pelvic floor muscle rehabilitation exercises may also assist with ejaculatory control [11].

The aim of this study was to systematically review the evidence base for BTs in the management of PE.

Methods

Review Methods

The review was undertaken in accordance with the general principles recommended in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (<http://www.prismastatement.org/>). The review protocol is available from the Health Technology Assessment Programme website (<http://www.nets.nihr.ac.uk/projects/hta/131201>).

Literature Searches

The following databases were searched up to August 2014: MEDLINE; Embase; Cumulative Index to Nursing and Allied Health Literature; The Cochrane Library including the Cochrane Systematic Reviews Database, Cochrane Controlled Trials Register, Database of Abstracts of Reviews of Effects and the Health Technology Assessment database; ISI Web of Science,

including Science Citation Index, and the Conference Proceedings Citation Index-Science. The Medline search strategy is provided in Supplementary Appendix S1; it should be noted that the search was undertaken as part of a wider project assessing a variety of treatments for PE [12], and for this reason, the search was not specific to BTs. The U.S. Food and Drug Administration website and the European Medicines Agency website were also searched. Existing systematic reviews and relevant studies were also checked for eligible studies.

Eligibility Criteria

Randomized controlled trials (RCTs) in adult men with PE that evaluated BTs were eligible for inclusion. Studies comparing a BT against a waitlist control or against another therapy were eligible, as were studies comparing a combination of BT plus drug treatment against drug treatment alone. Studies were not included if the same BT was provided in both arms, as these were not considered to be assessing the effect of the BT (e.g., studies of drug plus behavioral treatment vs. behavioral alone). Theses and dissertations were not included. Non-English publications were included where sufficient data could be extracted from an English-language abstract or tables.

Outcomes

Relevant outcomes included intravaginal ejaculatory latency time (IELT), other measures of ejaculatory latency, and other outcomes such as sexual satisfaction, control over ejaculation, relationship satisfaction, self-esteem, quality of life, treatment acceptability, and adverse events.

Data Extraction and Synthesis

One reviewer performed data extraction of each study; all numerical data were then checked by a second reviewer. Where possible, data were presented as forest plots using Cochrane RevMan software (version 5.2; The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) (RevMan 2014) [13].

Assessment of Methodological Quality of Studies

Methodological quality of included RCTs was assessed using the Cochrane Collaboration risk of bias assessment criteria [14]. Completeness of outcome data was considered low risk if the percentage of randomized participants excluded from the primary analysis was less than 30%. Selective reporting was considered low risk if IELT or ejaculatory latency was reported, and all outcomes

referred to in the study methods were reported. Overall risk of bias for each study was classed as “low” or “high” if they were rated as such for each of three key domains: allocation concealment, blinding of outcome assessment, and completeness of outcome data; otherwise, overall risk of bias was classed as “unclear.”

Results

Quantity of Evidence

The searches identified 2,283 citations (as part of a wider project assessing a variety of treatments for PE). Eighteen full-text articles were obtained as potentially relevant. A total of 10 RCTs (521 randomized participants) evaluating a BT for PE were included in the review.

Characteristics of Included Studies

Details of the included study characteristics are presented in Table 1. As noted earlier, BTs for PE include two main types of therapy: first, psychotherapeutic or counseling approaches, and second physical techniques. Interestingly, this review identified only one RCT involving psychotherapy for PE: a Chinese study [19] in which one group received a combination of drug treatment (chlorpromazine) plus psychotherapy (to reduce anxiety, sadness, and negative thoughts and rebuild confidence) plus the stop-start technique, whereas the other group received chlorpromazine alone. All other included RCTs focused on physical techniques, either individually or in combination. The specific BTs that were evaluated included: the squeeze technique [22]; the stop-start technique [21,23]; the stop-start and squeeze techniques [15]; the stop-start technique plus psychotherapy [19]; functional-sexological treatment involving education on sensuality, movement of the body, speed of sexual activity, muscular tension and breathing [15]; self-help material (covering squeeze technique, pause technique, and sensate focusing) with or without therapist phone contact [17]; sexual therapy for couples (sensate focus, stop-start technique, and communication exercises) [17]; pelvic floor muscle rehabilitation (awareness of muscle contraction) plus electrical stimulation of perineal floor [11]; squeeze technique, sensate focus, and Chinese traditional *Qigong* treatment (penis swinging and acupoint tapping) [20]; web-based sex therapy based on sensate-focus [18]; and the stop-start technique using a handheld vibrating stimulation device [16].

Table 1 Study characteristics and risk of bias

RCT Country Duration N randomized	Treatments (N randomized)	PE definition Lifelong/acquired	Risk of bias assessment					Overall risk*	
			Random sequence generation	Allocation concealment	Blinding of participants/personnel	Blinding of outcome assessment	Completeness of outcome data		Selective reporting†
Behavioral therapy vs. waitlist									
Canada n = 36 couples	— Functional-sexological therapy (education on sensuality, body movements, speed of activity, muscular tension, breathing) — Behavioral therapy (squeeze, stop-start) — Waitlist (total n = 36)	IELT < 2 minutes NR	Unclear	Unclear	Not possible	Unclear	Unclear	Low	Unclear
Finland n = 11	— Stop-start technique using handheld vibrational stimulation device (n = 6) — Waitlist (n = 5)	NR Lifelong	Unclear	Unclear	Not possible	Unclear	Unclear	Low	Unclear
Trudel and Proulx [17] Canada 12 weeks n = 25 couples	— Self-help book on behavioral techniques (bibliotherapy) — Self-help book + therapist phone contact — Sexual therapy for couples (sensate focus, stop-start, communication) — Waitlist (total n = 25)	IELT ≤ 5 minutes NR	Unclear	Unclear	Not possible	Unclear	Unclear	Low	Unclear
van Lankveld et al. [18] Netherlands 12 weeks n = 40	— Web-based sex therapy (sensate focus) (n = 22) — Waitlist (n = 18)	NR NR	Low	Unclear	Not possible	Unclear	Unclear	Low	Unclear
Combined therapies vs. monotherapy									
China 6 weeks n = 90	— Psychotherapy + stop-start + chlorpromazine 50 mg/d (n = 45) — Chlorpromazine 50 mg/d (n = 45)	IELT < 1 minute NR	Unclear in English language text	Unclear in English language text	Not possible	Unclear in English language text	Unclear	Low	Unclear
Shao and Li [20] China 8 weeks n = 120	— Behavioral therapy (squeeze, sensate focus, Qigong, acupoints; 8 weeks) (n = 40) — Paroxetine 20 mg/d (8 weeks) (n = 40) — Behavioral therapy (8 weeks) + paroxetine 10 mg/d (4 weeks) (n = 40)	NR NR	Unclear in English language text	Unclear in English language text	Not possible	Unclear in English language text	Unclear	Low	Unclear
Yuan et al. [21] China 6 weeks n = 96	— Behavioral therapy (stop-start) (n = 32) — Citalopram 20 mg/d (n = 32) — Behavioral therapy + citalopram (n = 32)	NR NR	Unclear in English language text	Unclear in English language text	Not possible	Unclear in English language text	Unclear	Low	Unclear
Behavioral therapy vs. drug treatment									
Egypt Crossover, 4 weeks each, 2-week washouts n = 31	— Behavioral (squeeze technique) — Clomipramine 25 mg — Sertraline 50 mg — Paroxetine 20 mg — Sildenafil 50 mg (all 3–5 hours pre-coitus) (total n = 31)	IELT ≤ 2 minutes Lifelong	Unclear	Low	Not possible	Unclear	Unclear	Low	Unclear
Oguzhanliu et al. [23] Turkey 8 weeks N = 32	— Stop-start technique (n = 16) — Fluoxetine 20 mg/d (n = 16)	Ejaculation within several minutes Lifelong and acquired	Unclear	Unclear	Not possible	Unclear	Unclear	High	Unclear
Pastore et al. [11] Italy 12 weeks n = 40	— Pelvic floor muscle rehabilitation + electrical stimulation of perineum, 3 sessions/week (n = 19) — Dapoxetine 30–60 mg on-demand (n = 21)	ISSM definition PE Lifelong	Low	Unclear	Not possible	Unclear	Unclear	Low	Unclear

CIPe-5 = Chinese Index of Premature Ejaculation-5; GRISS = Golombok Rust Inventory of Sexual Satisfaction; IELT = intravaginal ejaculatory latency time; ISSM = International Society for Sexual Medicine; NR = not reported; PE = premature ejaculation; RCT = randomized controlled trial.

*Completeness of outcome data = low risk if <30% excluded from primary analysis.

†Selective reporting = low risk if reported IELT/ejaculatory latency and all outcomes referred to in methods.

‡Overall risk of bias = "low" or "high" if rated as such for allocation concealment, blinding of outcome assessment, and completeness of outcome data.

Duration of the behavioral intervention in the included studies ranged from 2 to 12 weeks. Four studies compared one or more behavioral techniques with a waitlist control [15–18]. Three further studies compared a BT with one or more drug treatments [11,22,23], whereas another three studies compared combined therapy (behavioral and drug) vs. drug treatment alone [19–21].

Studies were conducted in a range of countries: three in China (published in Chinese language) [19–21], two in Canada [15,17], and one each in Egypt [22], Turkey [23], Italy [11], the Netherlands [18], and Finland [16]. The definition of PE was an IELT of <1 minute in one study [19], ≤ 2 minutes in two studies [15,22], ≤ 5 minutes in one study [17], defined according to the ISSM definition in one study [11], “before or within several minutes” in one study [23], and was not reported (or not available in the English language text) in four studies [16,18,20,21]. Three studies reported that participants had lifelong PE [11,16,22], whereas in one study participants had lifelong or acquired PE [23]; for the remaining studies, this was not reported (or not available in the English language text).

Of the 10 studies, one did not report IELT [23], whereas the remaining nine reported either IELT (in minutes) or another measure of ejaculatory latency (Table 2). Of these, four studies reported stopwatch-assessed IELT [11,15,16,22]; three studies reported IELT in minutes, but the measurement method was not reported (or not available in English-language text) [17,19,21]; one study reported tendency to ejaculate too soon as measured via the Golombok Rust Inventory of Sexual Satisfaction (GRISS) PE subscale [18]; and one study reported ejaculatory latency as measured on the Chinese Index of Premature Ejaculation-5 (CIPE-5) five-point Likert scale [20].

Risk of Bias in Included Studies

The risk of bias within included studies is shown in Table 1. All 10 studies were classed as overall unclear risk of bias due to limited reporting of methodological details (three studies [19–21] were reported in Chinese, and some details were unavailable from the English language text). In total, eight studies [15–17,19–23] were unclear in terms of randomization sequence generation and nine [11,15–21,23] were unclear in terms of allocation concealment. Due to the nature of the interventions, blinding of participants and personnel was not possible in any study. Blinding of outcome assessment was unclear in all studies.

Eight studies [11,16,18–23] were considered at low risk of bias for completeness of outcome data (<30% excluded from primary analysis), whereas two [15,17] were unclear on this point. All studies scored low for selective reporting (based on the fact that they reported IELT or ejaculatory latency as well as all outcomes referred to in the methods sections), with the exception of one study [23] that did not report IELT or ejaculatory latency.

Assessment of Effectiveness: IELT and Ejaculatory Latency

BT vs. Waitlist

Four studies assessed BTs vs. waitlist control [15–18]. Two significantly favored BTs in terms of IELT, whereas one showed no difference on another measure of ejaculatory latency (Table 2; Figures 1–3).

Functional-Sexological Treatment or Squeeze/ Stop-Start vs. Waitlist

A study by de Carufel and Trudel (2006; $n = 36$ couples) [15] assessed two types of BT vs. waitlist control: functional-sexological therapy (FS, involving education on sensuality, movement of the body, speed of sexual activity, muscular tension and breathing) and BT (involving the squeeze and stop-start techniques). Duration of treatment was not reported. Both treatments improved stopwatch-measured IELT significantly more than waitlist at posttreatment, by almost 7 minutes (Table 2; Figure 1). Follow-up data 3 months post-treatment was available for the FS and BT groups (though not for waitlist); in both groups, the significant change in IELT from baseline to post-treatment remained significant 3 months after treatment cessation.

Stop-Start Using Handheld Device vs. Waitlist

A small study by Jern ($n = 11$ participants) [16] assessed the stop-start technique aided by a handheld vibrating stimulation device vs. waitlist control. Participants used the device, alone or with a partner, three times per week for 6 weeks. After 6 weeks, ejaculatory latency improved slightly more in the treatment group (improvement of 1.6 minutes; $P = 0.019$ for change from baseline) than in the waitlist group (0.9 minutes; $P = 0.075$ for change); however, the posttreatment scores were not significantly different (mean difference [MD] 0.35 minutes, 95% confidence interval [CI] –2.26 to 2.96; $P = 0.79$; Table 2 and Figure 1). At follow-up 6 months after all patients undertook

Table 2 Results for IELT and ejaculatory latency

RCT	Country	Duration	N randomized	Treatments (N randomized per group)	Outcome: IELT or ejaculatory latency	Results	Effect estimate (95% CI)	Significant difference?
Behavioral therapy vs. waitlist								
De Carufel and Trudel [15]	Canada	NR	n = 36 couples	<ul style="list-style-type: none"> — Functional-sexological therapy (FS) — Behavioral therapy (BT; squeeze, stop-start) — Waitlist (total n = 36) 	IELT (stopwatch)	Posttreatment mean (minutes): <ul style="list-style-type: none"> — FS: 7.80 (SD 3.74), n = 18 — BT: 7.87 (SD 3.77), n = 18 — Waitlist: 1.00 (SD 0.69), n = 18 — 3-month follow-up mean (mins): FS: 6.88 (SD 4.62), n = 18 — BT: 8.18 (SD 5.41), n = 18 	BT vs. waitlist (posttreatment): <ul style="list-style-type: none"> — FS: MD = 6.80 (5.04 to 8.56), $P < 0.00001$ — BT: MD = 6.87 (5.10 to 8.64), $P < 0.00001$ Significant change baseline to post-treatment maintained at 3-month follow-up (FS, BT)	Yes (favors BT groups)
Jern [16]	Finland	6 weeks	n = 11	<ul style="list-style-type: none"> — Stop-start using handheld vibrating stimulation device (n = 6) — Waitlist (n = 5) 	IELT (stopwatch)	Posttreatment mean (mins): <ul style="list-style-type: none"> — BT: 2.91 (SD 1.23), n = 5; change +1.60 minutes — WL: 2.56 (SD 2.71), n = 5; change +0.90 minutes ($P = 0.075$ for change) <ul style="list-style-type: none"> — 6-month follow-up mean (mins): BT: 3.36 (SD 1.16), n = 9; change +1.74 minutes ($P = 0.008$ for change)	Significant change from baseline to 6-month follow-up after all patients undertook BT	No (but improved from baseline)
Trudel and Proulx [17]	Canada	12 weeks	n = 25 couples	<ul style="list-style-type: none"> — Self-help book — Self-help book + therapist phone contact — Sexual therapy for couples — Waitlist (total n = 25) 	IELT (method NR)	Posttreatment mean (mins): <ul style="list-style-type: none"> — Self-help: 11.05 — Self-help + phone: 9.23 — Sexual therapy: 10.78 — Waitlist: 1.94 (No SDs reported)	BT vs. waitlist: <ul style="list-style-type: none"> — Self-help: MD = 9.11 — Self-help + phone: MD = 7.29 — Sexual therapy: MD = 8.84 	Yes (favors BT groups)
van Lankveld et al. [18]	Netherlands	12 weeks	n = 40	<ul style="list-style-type: none"> — Web-based sex therapy (sensate focus) (n = 22) — Waitlist (n = 18) 	Tendency to ejaculate too soon (GRISS-PE subscale)	Posttreatment mean (GRISS-PE): <ul style="list-style-type: none"> — Sex therapy: 13.2 (SD 2.5), n = 21 — Waitlist: 13.4 (SD 2.3), n = 16 3-month follow-up (GRISS-PE): <ul style="list-style-type: none"> — Sex therapy: 12.9 (SD 3.2) — 6-month follow-up (GRISS-PE): Sex therapy: 13.4 (SD 3.1) 	Significant change baseline to posttreatment, BT ($P < 0.01$) but not waitlist ($P = NS$). Changes (BT) maintained at 3-month follow-up MD = -0.20 (-1.75 to 1.35), $P = 0.80$	No (but improved from baseline)
Li et al. [19]	China	6 weeks	n = 90	Behavioral + drug therapies vs. drug alone <ul style="list-style-type: none"> — Psychotherapy + stop-start + chlorpromazine 50 mg/d (n = 45) — Chlorpromazine 50 mg/d (n = 45) 	IELT (method NR)	Posttreatment mean (mins): <ul style="list-style-type: none"> — BT + chlor: 5.87 (SD 0.59), n = 41 — Chlor: 4.76 (SD 0.54), n = 40 	Combined vs. drug: MD = 1.11 (0.86–1.36), $P < 0.0001$	Yes (favors combined)

Table 2 Continued

RCT Country Duration N randomized	Treatments (N randomized per group)	Outcome: IELT or ejaculatory latency	Results	Effect estimate (95% CI)	Significant difference?
Shao and Li [20] China 8 weeks n = 80 for this comparison	— Behavioral therapy (squeeze, sensate focus, Qigong, acupoint; 8 weeks) + paroxetine 10 mg/d (4 weeks) (n = 40) — Paroxetine 20 mg/d (8 weeks) (n = 40)	Ejaculatory latency (CIPE-5, five-point scale, higher = improved)	Posttreatment mean (CIPE-5): — BT + parox: 4.8 (SD 0.5), n = 40 — Parox: 4.4 (SD 0.5), n = 40	Combined vs. drug: MD = 0.40 (0.18–0.62), P = 0.0003	Yes (favors combined)
Yuan et al. [21] China 6 weeks n = 64 for this comparison	— Behavioral therapy (stop-start) + citalopram (n = 32) — Citalopram 20 mg/d (n = 32)	IELT (method NR)	Post-treatment mean (mins): — BT + citat: 6.22 (SD 0.91), n = 32 — Citalopram: 5.76 (SD 0.79), n = 32	Combined vs. drug: MD = 0.46 (0.04–0.88), P = 0.03	Yes (favors combined)
Behavioral therapy vs. drug treatment					
Abdel-Hamid et al. [22] Egypt Crossover, 4 weeks each, 2-week washouts n = 31	— Behavioral (squeeze technique) — Clomipramine 25 mg — Sertraline 50 mg — Paroxetine 20 mg — Sildenafil 50 mg (all 3–5 hours pre-coitus) (total n = 31) — Pelvic floor rehabilitation + electrical stimulation (n = 19) — Dapoxetine 30 or 60 mg on-demand (n = 21)	IELT (stopwatch)	Posttreatment, median (mins): — Behavioral (squeeze): 3 — Clomipramine: 4 — Sertraline: 3 — Paroxetine: 4 — Sildenafil: 15	Favors sildenafil or paroxetine vs. pause-squeeze; other comparisons not significant (no further data)	Yes (favors drug for 2 of 4 drugs)
Pastore et al. [11] Italy 12 weeks n = 40	— Pelvic floor rehabilitation + electrical stimulation (n = 19) — Dapoxetine 30 or 60 mg on-demand (n = 21)	IELT (stopwatch)	Posttreatment, geometric mean (mins): — Pelvic floor: 2.10 (SD 0.62), n = 17 — Dapoxetine: 3.32 (SD 0.62), n = 15	BT vs. drug: MD = -1.22 (-1.65 to -0.79), P < 0.00001	Yes (favors drug)
Shao and Li [20] China 8 weeks n = 80 for this comparison	— Behavioral therapy (squeeze, sensate focus, Qigong, acupoint) (n = 40) — Paroxetine 20 mg/d (n = 40)	Ejaculatory latency (CIPE-5, five-point scale, higher = improved)	Post-treatment mean (CIPE-5): — BT: 4.2 (SD 0.4), n = 40 — Parox: 4.4 (SD 0.5), n = 40	BT vs. drug: MD = -0.20 (-0.40 to 0.00), P = 0.05	Yes (favors drug)
Yuan et al. [21] China 2 weeks n = 64 for this comparison	— Behavioral therapy (stop-start) (n = 32) — Citalopram 20 mg/d (n = 32)	IELT (method NR)	Posttreatment mean (mins): — BT: 2.21 (SD 0.53), n = 32 — Citalopram: 5.76 (SD 0.79), n = 32	BT vs. drug: MD = -3.55 (-3.88 to -3.22), P < 0.00001	Yes (favors drug)

BT = behavioral therapy; CI = confidence interval; CIPE-5 = Chinese Index of Premature Ejaculation-5; FS = functional-sexological therapy; GRISS = Golombok Rust Inventory of Sexual Satisfaction; IELT = intra-vaginal ejaculatory latency time; MD = mean difference; NR = not reported; PE = premature ejaculation; RCT = randomized controlled trial; RR = relative risk; SD = standard deviation.




Figure 1 Behavioral therapies vs. waitlist: IELT and ejaculatory latency

treatment, IELT had improved by 1.7 minutes from baseline (P = 0.008 for change).

Self-Help Book with/Without Therapist Contact or Couples' Sexual Therapy vs. Waitlist

A further RCT by Trudel and Proulx (n = 25 couples) [17] assessed three types of BT vs. waitlist control: self-help book alone (described as

bibliotherapy); self-help book plus therapist phone contact; and sexual therapy for couples. After 12 weeks, all gave improvements in IELT of between 7 and 9 minutes over that of the waitlist group, though the method of IELT measurement was not stated, with changes from baseline significant for all treatment groups (P < 0.01) but not for the waitlist group (P value not reported; Table 2).




Figure 2 Behavioral plus drug therapy vs. drug alone: IELT and ejaculatory latency




Figure 3 Behavioral therapy vs. drug treatment: IELT and ejaculatory latency

These data could not be presented on the forest plot as no standard deviations were reported. Changes from baseline in the treatment groups remained significant 3 and 6 months after treatment cessation.

Web-Based Sex Therapy vs. Waitlist

A third RCT by van Lankveld et al. [18] (n = 40 participants) assessed web-based sex therapy (using sensate focus) vs. waitlist. The GRISS-PE subscale was used to measure the extent to which a man has the tendency to ejaculate too soon. There was almost no difference between groups at 12 weeks (score of 13 in both groups; $P = 0.80$; Table 2 and Figure 1). Both groups improved from baseline ($P < 0.001$), and the change in the sex therapy group remained significant at 3 and 6 months after treatment cessation (no follow-up data were available for waitlist).

Combined Behavioral and Drug Therapy vs. Drug Alone

Three studies compared behavioral and drug combination therapy vs. drug treatment alone; all showed small but significant differences in IELT or ejaculatory latency favoring the combined approach [19–21].

BT Plus Chlorpromazine vs. Chlorpromazine

One RCT by Li et al. (n = 90 participants) [19] assessed combined therapy (BT plus chlorpromazine, a dopamine antagonist; 50 mg/day) vs. chlorpromazine alone. BT consisted of the stop-start technique plus psychotherapy (to reduce

anxiety, sadness, and negative thoughts and rebuild confidence). Combined therapy gave a greater increase in IELT at 6 weeks, though the difference was only 1 minute, and the measurement method was not reported (MD 1.11 minutes, 95% CI 0.86 to 1.36; $P < 0.00001$; Table 2 and Figure 2).

BT Plus Paroxetine vs. Paroxetine

Another RCT by Shao et al. (n = 80 participants for this comparison) [20] assessed BT plus paroxetine (a selective serotonin reuptake inhibitor [SSRI]) vs. paroxetine alone. BT included squeeze technique, sensate focus, Qigong and acupoint tapping and was provided for 8 weeks. The paroxetine dose was 10 mg/day for 4 weeks in the combined therapy group and 20 mg/day for 8 weeks in the paroxetine-only group. Combined therapy was superior to paroxetine alone in increasing ejaculatory latency at 8 weeks as measured on a five-point Likert scale via the CIPE-5, though the difference was small (MD 0.40, 95% CI 0.18 to 0.62; $P = 0.0003$; Table 2 and Figure 2).

BT Plus Citalopram vs. Citalopram

A further RCT by Yuan et al. (n = 64 participants for this comparison) [21] reported that BT (stop-start technique) plus citalopram (an SSRI; 20 mg/day) was superior to citalopram alone in increasing IELT at 6 weeks, though the IELT difference was only 0.5 minutes, and the measurement method was not reported (MD 0.46 minutes, 95% CI 0.04 to 0.88; $P = 0.03$; Table 2 and Figure 2).

BT vs. Drug Treatment

Four studies compared BT alone vs. drug treatment alone; all showed small but significant differences in IELT or ejaculatory latency favoring drug treatment [11,20–22].

Pelvic Floor Rehabilitation vs. Dapoxetine

One RCT by Pastore et al. ($n = 40$ participants) [11] compared pelvic floor rehabilitation (plus electrical stimulation of the perineum) vs. dapoxetine (an SSRI, 30 or 60 mg taken prior to intercourse). The between-group difference in geometric mean stopwatch-assessed IELT at 12 weeks was 1.22 minutes in favor of dapoxetine (MD 1.22, 95% CI 0.79 to 1.65; $P < 0.0001$; Table 2 and Figure 3).

BT vs. Paroxetine

The RCT by Shao et al. ($n = 80$ participants for this comparison) [20] compared paroxetine (20 mg/day) against BT (squeeze technique, sensate focus, Qigong and acupoint tapping). The between-group difference in the CIPE-5 ejaculatory latency score at 8 weeks significantly favored paroxetine (MD 0.20, 95% CI 0.00 to 0.40; $P = 0.05$; Table 2 and Figure 3).

BT vs. Citalopram

The RCT by Yuan et al. ($n = 64$ participants for this comparison) [21] reported a between-group difference in IELT at 6 weeks of 3.55 minutes in favor of citalopram (20 mg/day) compared with BT (stop-start technique); MD 3.55, 95% CI 3.22 to 3.88; $P < 0.00001$; Table 2 and Figure 3). The measurement method was not reported.

Squeeze Technique vs. SSRIs or Tricyclic Antidepressants (TCA)

The between-group difference in median stopwatch-measured IELT following a 4-week randomized crossover comparison (Abdel-Hamid et al.; $n = 31$ participants) [22] significantly favored sildenafil or paroxetine over BT (pause-squeeze technique), whereas comparisons with sertraline and clomipramine were not significant (Table 2). Data were not presented on the forest plot due to the reporting of median rather than mean values.

Assessment of Effectiveness: Non-IELT Outcomes

With the exception of the RCT by Pastore et al. [24], all of the included trials were reported as evaluating one or more outcomes other than IELT (Table 3). However, these were diverse across the

included trials and were not reported in sufficient detail to permit any pooling across trials.

BT vs. Waitlist Control

Four RCTs assessed non-IELT outcomes for BTs vs. waitlist control; one significantly favored BTs [15], whereas the other two were unclear as to whether there was a significant difference between groups [16–18]. One RCT (de Carufel and Trudel) [15] showed significant improvements in male perception of duration of intercourse and couples' sexual satisfaction with either functional sexological treatment (sensual education) or BT (stop-start technique and squeeze technique) compared with waitlist control. Another RCT (Trudel and Proulx) [17] reported a significant increase from baseline in sexual satisfaction for all three BT groups (self-help book, self-help book plus therapist phone contact, and sexual therapy) with better results for self-help plus phone contact vs. self-help alone; however, no data were reported for the waitlist group. A further RCT (van Lankveld et al.) [18] reported that sexual desire improved significantly more with web-based sensate focus than waitlist control, whereas sexual satisfaction improved from baseline but showed no significant difference between groups; conversely, self-confidence showed no significant difference either between groups or from baseline. A small RCT using the stop-start technique aided by a handheld stimulation device (Jern) [16] showed no significant improvement over waitlist or from baseline post-treatment (via a composite score for ejaculatory latency, control and relationship problems); however, a significant improvement from baseline was observed at 6-month follow-up (at which point all patients had received treatment so there was no waitlist comparison).

Combined Behavioral + Drug Therapy vs. Drug Alone

Three RCTs reported better results for combined therapy (behavioral plus drug) than drug treatment alone on a range of non-IELT outcomes [19–21]. BT (stop-start plus psychotherapy) combined with chlorpromazine was reported by one RCT as being more effective than chlorpromazine alone on a self-rated measure of anxiety and CIPE measures of sexual anxiety, sexual satisfaction, and ejaculatory control (Li et al.) [19]. Another RCT (Shao et al.) [20] reported that combined treatment with paroxetine plus BT (squeeze, sensate focus, Qigong and acupoint tapping) was superior to paroxetine alone on CIPE measures of ejaculatory control, patient/partner satisfaction, and

Table 3 Results for outcomes other than IELT

RCT	Country	Duration	N randomized	Treatments (N randomized per group)	Outcome measure	Results	Significant difference?
Behavioral therapy vs. waitlist							
De Carufel and Trudel [15]							
Canada				— Functional-sexological therapy	Sexual satisfaction (Hudson's index)	Both treatment groups had significant improvements over waitlist (men and partners)	Yes (favors BT groups)
NR				— Behavioral therapy (squeeze, stop-start)	Perception of duration of intercourse	Improved significantly with both treatments (men; $P < 0.05$) but not waitlist	Yes (favors BT groups)
NR				— Waitlist (total n = 36)			
Jern [16]				— Stop-start using handheld vibrating stimulation device (n = 6)	Ejaculatory control, latency, relationship problems (CHEES)	Posttreatment, no significant between-group difference or change from baseline	No (also no improvement from baseline)
Finland				— Waitlist (n = 5)		At 6 months, significant improvement from baseline after all patients undertook BT ($P = 0.006$)	Significant improvement from baseline
6 weeks							
n = 11							
Trudel and Proulx [17]							
Canada				— Self-help book	Sexual satisfaction (SI)	Improved in all three treatment groups for men and partners ($P < 0.05$); no data for waitlist group	Unclear (BT vs. waitlist)
12 weeks				— Self-help book + therapist phone contact		Self-help book + phone contact better than self-help book alone ($P < 0.05$)	Better with phone contact
12 weeks				— Sexual therapy for couples			
n = 25 couples				— Waitlist (total n = 25)			
van Lankveld et al. [18]				— Web-based sex therapy (sensate focus)	Sexual desire (IIEF)	Favored sex therapy vs. waitlist ($P < 0.05$). Improved from baseline across groups ($P < 0.05$); maintained at 3- and 6-month follow-up	Yes (also improved from baseline)
Netherlands				— Waitlist (n = 18)		No between-group difference. Improved from baseline across groups ($P = 0.005$); maintained at 3- and 6-month follow-up	No (both groups improved from baseline)
12 weeks					Overall satisfaction (IIEF)	No between-group difference. No significant change from baseline to post-treatment	No (also no improvement from baseline)
n = 40					Self-confidence (SEAR)		
Behavioral + drug therapies vs. drug alone							
Li et al. [19]							
China				— Psychotherapy + stop-start + chlorpromazine 50 mg/d (n = 45)	Sexual satisfaction (patient & partner), ejaculatory control, ejaculatory latency (CIPE)	Chlorpromazine + BT superior to chlorpromazine alone for all outcomes ($P < 0.05$)	Yes (favors combined)
6 weeks				— Chlorpromazine 50 mg/d (n = 45)	Anxiety (SAS and CIPE)		Yes (favors combined)
n = 90							
Shao and Li [20]				— Behavioral therapy (squeeze, sensate focus, Qigong, acupoint, 8 weeks) + paroxetine 10 mg/d (4 weeks) (n = 40)	Ejaculatory control (CIPE-5)	BT + paroxetine better than paroxetine ($P < 0.01$)	Yes (favors combined)
China				— Paroxetine 20 mg/d (8 weeks) (n = 40)	Partner/partner satisfaction (CIPE-5)	BT + paroxetine better than paroxetine ($P < 0.05$)	Yes (favors combined)
8 weeks					Sexual anxiety (CIPE-5)		Yes (favors combined)
n = 80 for this comparison				— Behavioral therapy (stop-start) + citalopram (n = 32)	Sexual satisfaction (measure NR)	Favored BT + citalopram vs. citalopram alone ($P = NR$)	Unclear
Yuan et al. [21]				— Citalopram 20 mg/d (n = 32)			
China							
2 weeks							
n = 64 for this comparison							
Behavioral therapy vs. drug treatment							
Abdel-Hamid et al. [22]							
Egypt				— Behavioral (squeeze)	Sexual satisfaction (modified EDITS)	Medians: squeeze technique, 6; clomipramine, 11; sertraline, 10; sildenafil, 30; paroxetine, 12	Yes (sildenafil or paroxetine superior to BT; others not significant)
Crossover, 4 weeks each, 2-week washouts				— Clomipramine 25 mg			
n = 31				— Sertraline 50 mg	Anxiety (AAI, scale 0 to 30)	Medians: squeeze technique, 12; clomipramine, 11; sertraline, 11; sildenafil, 8; paroxetine, 9	No
				— Paroxetine 20 mg			
				— Sildenafil 50 mg (all 3–5 hours pre-coitus)			
Oguzhanglu et al. [23]				— Stop-start technique (n = 16)	Sexual satisfaction (latency and control in 75% coitus)	No difference between groups ($P > 0.05$); significantly improved in both groups	No (improved from baseline)
Turkey				— Fluoxetine 20 mg/d (n = 16)	Anxiety (STAI)	Anxiety (state and trait) improved from baseline in both groups ($P < 0.05$)	No (improved from baseline)
8 weeks							
n = 32							
Pastore et al. [11]				— Pelvic floor rehabilitation + electrical stimulation (n = 19)	No other outcomes reported	—	—
Italy				— Dapoxetine 30–60 mg (n = 21)			
12 weeks							
n = 40							
Shao and Li [20]				— Behavioral therapy (squeeze, sensate focus, Qigong, acupoint) (n = 40)	Ejaculatory control (CIPE-5)	Paroxetine better than BT ($P < 0.01$)	Yes (favors drug)
China				— Paroxetine 20 mg per day (n = 40)	Partner/partner satisfaction (CIPE-5)	BT better than paroxetine ($P < 0.01$)	Yes (favors BT)
8 weeks					Sexual anxiety (CIPE-5)		No difference
n = 80 for this comparison							
Yuan et al. [21]				— Behavioral therapy (stop-start) (n = 32)	Sexual satisfaction (measure NR)	Citalopram significantly superior to BT ($P = 0.015$)	Yes (favors drug)
China				— Citalopram 20 mg/d (n = 32)			
2 weeks							
n = 64							

AAI = Arabic Anxiety Inventory; BT = behavioral therapy; CHEES = Checklist for Early Ejaculation Symptoms; CIPE-5 = Chinese Index of Premature Ejaculation-5; EDITS = Erectile Dysfunction Inventory of Treatment Satisfaction; IIEF = International Index of Erectile Function; NR = not reported; RCT = randomized controlled trial; SAS = Self-rating Anxiety Scale; SEAR = Self-Esteem and Relationship; STAI = State-Trait Anxiety Index.

sexual anxiety. A further RCT (Yuan et al.) [21] reported that BT (stop-start technique) combined with citalopram was more effective at improving sexual satisfaction than citalopram alone, though significance level was not reported.

BT vs. Drug Treatment

Four RCTs [20–23] comparing BTs vs. drug treatment reported non-IELT outcomes, with mixed results (some outcomes favoring drug treatment, some behavioral, and some showing no difference). One RCT (Shao et al.) [20] reported mixed results; results for CIPE-assessed ejaculatory control significantly favored paroxetine over BT, whereas results for patient/partner satisfaction significantly favored BT, and there was no significant difference in sexual anxiety. Yuan et al. [21] reported that citalopram significantly improved sexual satisfaction compared with BT (stop-start). Oguzhanglu et al. [23] reported no significant between-group difference in sexual satisfaction for stop-start technique compared with fluoxetine (though both groups improved from baseline). A crossover RCT (Abdel-Hamid et al.) [22] reported significantly better sexual satisfaction with sildenafil or paroxetine compared with the squeeze technique but no significant differences compared with clomipramine or sertraline, whereas anxiety was not significantly different between groups.

Assessment of Adverse Effects and Withdrawals from Treatment

Adverse effect data were available for six of 10 studies [11,16,17,20,22,23]. None reported any adverse effects for BTs. One study (Trudel and Proulx) [17] reported that dropout rates from treatment were higher for the group receiving self-help material alone (45%) than for the two groups with therapist contact (14% and 33%; unclear which data relate to which of the two therapist-contact groups).

Adverse event rates reported for groups receiving drug treatment or combined drug and behavioral treatment were as follows: 10% for paroxetine 10 mg/day (plus BT) [20]; 40% for paroxetine 20 mg/day [20]; 17% for paroxetine 20 mg taken pre-coitus [22]; 10% for sertraline 50 mg pre-coitus [22], 13% for fluoxetine [23]; 13% for dapoxetine 30 mg pre-coitus [11]; 29% for dapoxetine 60 mg pre-coitus [11]; 25% for clomipramine 25 mg pre-coitus [22]; and 18% for sildenafil 50 mg pre-coitus [22]. Where reported, adverse effects of SSRIs included nausea, diarrhea,

dry mouth, anorexia, drowsiness, and yawning [11,22,23], whereas adverse effects of sildenafil (phosphodiesterase type 5 inhibitors) included headache, flushing, and nasal congestion [22].

Summary of Effectiveness Results

The effectiveness results across trials are summarized in Table 4. Four trials compared BTs against waitlist [15–18]. Of these, two trials assessing five types of BT reported posttreatment differences in IELT of 7–9 minutes compared with the waitlist groups, with changes in the treatment groups maintained 3 months after treatment cessation [15,17]. However, a further trial showed no difference in ejaculatory latency via the GRISS-PE scale between web-based sensate focus and waitlist, though both groups improved from baseline [18]. Another trial showed no posttreatment difference in IELT between the stop-start technique aided by a stimulation device vs. waitlist, though there was a significant improvement from baseline at 6-month follow-up [16]. Results were mixed for other outcomes (sexual satisfaction, desire, and self-confidence), with some waitlist comparisons significantly favoring BT while others were not significant [15–18].

Three trials favored combined behavioral and drug treatment over drug treatment alone [19–21], with small but significant differences in IELT favoring combined treatment (0.5–1 minute across two trials) [19,21] and significantly better results for combined treatment on other outcomes (sexual satisfaction, ejaculatory control, and anxiety) [19–21]. Direct comparisons of BT alone or drug treatment alone gave mixed results both for IELT and other outcomes, with most findings either favoring drug treatment or showing no significant difference.

Discussion

This systematic review assesses the effectiveness of BTs for the treatment of PE, based on RCT evidence. Ten trials were identified; these were conducted across various countries and the overall risk of bias was unclear in all studies. The included studies assessed various types of BT either individually or in combination, including the squeeze and stop-start techniques, stop-start aided by a stimulation device, education on sensuality and movement, sensate focus, and pelvic floor muscle rehabilitation. All the above showed some evidence of effectiveness either over waitlist or as an

Table 4 Summary of results

Outcome	RCTs	N pips	Intervention	Comparator	Mean diff. (95% CI), P value	Favors
Behavioral therapy vs. waitlist						
IELT (minutes)	de Carufel and Trudel [15]	36	BT (squeeze, stop-start)	Waitlist	6.87 (5.10 to 8.64), $P < 0.00001$	BT
	Trudel and Proulx [17]	25	BT (FS) BT (self-help) BT (self-help + phone) BT (couples therapy) BT (stop-start + device)	Waitlist	6.80 (5.04 to 8.56), $P < 0.00001$	BT
	Jern [16]	11	BT (web-based sensate focus)	Waitlist	7.29 (NR)	BT
	van Lankveld et al. [18]	40	BT (two types; see above) BT (three types; see above) BT (web-based sensate focus)	Waitlist	8.84 (NR)	BT
Ejaculatory latency (GRISS-PE)	de Carufel and Trudel [15]	36	BT (two types; see above)	Waitlist	0.35 (-2.26 to 2.96), $P = 0.79$	Not significant
Sexual satisfaction	van Lankveld et al. [18]	40	BT (web-based sensate focus)	Waitlist	-0.20 (-1.75 to 1.35), $p=0.80$	Not significant
Perception of duration	van Lankveld et al. [18]	40	BT (web-based sensate focus)	Waitlist	$P = NR$	BT
Sexual desire	van Lankveld et al. [18]	40	BT (web-based sensate focus)	Waitlist	$P = NR$	Unclear
Self-confidence	van Lankveld et al. [18]	40	BT (web-based sensate focus)	Waitlist	$P = NR$	Not significant
Ejaculatory control, latency, problems	Jern [16]	11	BT (stop-start + device)	Waitlist	$P = NR$	Not significant
Behavioral + drug therapies vs. drug alone						
IELT (minutes)	Li et al. [19]	90	BT (PS + SS) + chlorpromazine	Chlorpromazine	1.11 (0.86 to 1.36), $P < 0.0001$	BT + drug
	Yuan et al. [21]	64	BT (stop-start) + citalopram	Citalopram	0.46 (0.04 to 0.88), $P = 0.03$	BT + drug
Ejaculatory latency (CIPE-5)	Li et al. [19]	90	BT (PS + SS) + chlorpromazine	Chlorpromazine	$P < 0.05$	BT + drug
Sexual satisfaction	Shao and Li [20]	80	BT (various) + paroxetine	Paroxetine	0.46 (0.04 to 0.88), $P = 0.03$	BT + drug
	Li et al. [19]	90	BT (PS + SS) + chlorpromazine	Chlorpromazine	$P < 0.05$	BT + drug
	Shao and Li [20]	80	BT (various) + paroxetine	Paroxetine	$P < 0.05$	BT + drug
	Yuan et al. [21]	64	BT (stop-start) + citalopram	Citalopram	$P = NR$ (states favors BT + drug)	Unclear
Ejaculatory control	Li et al. [19]	90	BT (PS + SS) + chlorpromazine	Chlorpromazine	$P < 0.05$	BT + drug
	Shao and Li [20]	80	BT (various) + paroxetine	Paroxetine	$P < 0.01$	BT + drug
	Li et al. [19]	90	BT (PS + SS) + chlorpromazine	Chlorpromazine	$P < 0.05$	BT + drug
	Shao and Li [20]	80	BT (various) + paroxetine	Paroxetine	$P < 0.01$	BT + drug
Anxiety	Li et al. [19]	90	BT (PS + SS) + chlorpromazine	Chlorpromazine	$P < 0.05$	BT + drug
	Shao and Li [20]	80	BT (various) + paroxetine	Paroxetine	$P < 0.01$	BT + drug
Behavioral therapy vs. drug treatment						
IELT (minutes)	Abdel-Hamid et al. [22]	31	BT (squeeze)	Paroxetine Sertraline Clomipramine	Not reported	Drug Not significant Not significant
	Pastore et al. [11]	40	BT (pelvic floor)	Sildenafil	-1.22 (-1.65 to -0.79), $P < 0.00001$	Drug
	Yuan et al. [21]	64	BT (stop-start)	Dapoxetine	-3.55 (-3.88 to -3.22), $P < 0.00001$	Drug
Ejaculatory latency (CIPE-5)	Shao and Li [20]	80	BT (various)	Citalopram	-0.20 (-0.40 to 0.00), $p=0.05$	Drug
Sexual satisfaction	Abdel-Hamid et al. [22]	31	BT (squeeze)	Paroxetine Sertraline	Not reported	Drug Not significant
	Oguzhanglu et al. [23]	32	BT (stop-start)	Clomipramine		Not significant
	Shao and Li [20]	80	BT (various)	Sildenafil		Not significant
	Yuan et al. [21]	64	BT (stop-start)	Fluoxetine	$P > 0.05$	Drug
Ejaculatory control	Shao and Li [20]	80	BT (various)	Paroxetine	$P < 0.01$	Not significant
Anxiety	Abdel-Hamid et al. [22]	31	BT (squeeze)	Citalopram	$P = 0.015$	BT
	Oguzhanglu et al. [23]	32	BT (stop-start)	Paroxetine	$P < 0.01$	Drug
	Shao and Li [20]	80	BT (various)	Paroxetine	$P < 0.01$	Drug
	Abdel-Hamid et al. [22]	31	BT (squeeze)	See above	Not reported	Not significant
	Oguzhanglu et al. [23]	32	BT (stop-start)	Fluoxetine	Not reported	Not significant
	Shao and Li [20]	80	BT (various)	Paroxetine	$P = NR$	Not significant

BT = behavioral therapy; CI = confidence interval; CIPE-5 = Chinese Index of Premature Ejaculation-5; FS = functional-sexological; GRISS = Golombok Rust Inventory of Sexual Satisfaction; IELT = intra-vaginal ejaculatory latency time; MD = mean difference; NR = not reported; NS = nonsignificant; PE = premature ejaculation; PS = psychotherapy; RCT = randomized controlled trial; RR = risk ratio; SS = stop-start.

addition to drug treatment. No adverse effects were reported for BTs, though these were not well reported across trials. There were generally only one or two trials of each specific type of therapy, which limits the conclusions that can be drawn. Results of two trials each comparing either two or three different types of BT indicated that all were similarly effective [15,17].

Only one RCT, Li et al. [19], included a psychotherapeutic approach, comparing chlorpromazine plus the stop-start technique plus psychotherapy against chlorpromazine alone. The effectiveness of psychotherapy in this study was unclear due to the combined intervention and the use of an active control. All remaining RCTs focused on physical techniques as outlined above. Indeed, current PE guidelines note that the majority of psychotherapy studies are uncontrolled and nonblinded [1]. Therefore, there remains a need for well-conducted RCTs of psychotherapeutic approaches to PE.

Study treatments were relatively well-described in most studies, though some simply referred to an established technique (such as stop-start or sensate focus). Three of the included studies were in Chinese language. This review used robust methodology including thorough literature searching and data checking by two reviewers. Non-RCT studies were not included within this review as these were considered to be of lower methodological quality and would have provided limited information on effectiveness.

Duration of the behavioral interventions in the included studies ranged from 2 to 12 weeks. Three studies reported that IELT improvements were maintained 3–6 months after treatment cessation; however, in general, there is limited data regarding how long any positive effects would be maintained after treatment finishes and whether additional follow-up treatments might be required. This is a consideration both for BTs and for drug treatments within PE studies.

The majority of RCTs included an assessment of either IELT or another measure of ejaculatory latency, though the method of IELT measurement (e.g., via stopwatch) was not always reported. Many RCTs also reported other outcomes such as ejaculatory control, sexual satisfaction, and anxiety, though various different measures were used to assess these, and data were not always clearly reported. It is important that clinical studies aim to assess non-IELT aspects of PE, as highlighted in the recently updated ISSM definition of PE, which includes inability to delay ejaculation and negative

personal consequences in addition to reduced latency time [1].

In comparison with a pharmacological treatment, most BTs require a willingness of the man and his partner to engage with the therapy and practice the relevant techniques. The suitability of a BT is likely to depend on individual patient (and partner) preference; some people may prefer a behavioral option, whereas others may prefer a pharmacological approach. Combinations of medical and psychological approaches may be useful where there is a clear psychosocial or relationship issue [1].

In order to increase consistency in outcome data and facilitate meta-analyses, future studies should aim to recruit men meeting the ISSM definition of PE, measure stopwatch-assessed IELT, and report other aspects of PE in addition to IELT using validated instruments.

Further research may focus on psychotherapeutic or counseling approaches for PE, for which few RCTs were identified in the current evidence base. Combination therapy may also be worthy of further study; this may include combinations of physical techniques and counseling approaches, and/or behavioral and drug treatments. Additional areas for further study may include assessment of differences between types of BT, optimum duration of therapy, and how effects might best be maintained long-term.

Conclusions

There is limited evidence that physical behavioral techniques for PE improve IELT and other outcomes over waitlist control. There is also some evidence that BTs combined with drug treatments improve IELT and other outcomes compared with drug treatments alone. Areas for further research might include: RCTs of psychotherapeutic or counseling approaches to PE; further studies of combination therapy (physical/behavioral and/or counseling and/or drug); and assessment of how effects of therapy might be maintained long-term.

Acknowledgments

Thanks to Shijie Ren for translation of articles.

Corresponding Author: Katy Cooper, PhD, ScHARR, University of Sheffield, Regent Court, 30 Regent Street, Sheffield S1 4DA, UK. Tel: +44 (0)114 222 0773; Fax: +44 (0)114 272 4095; E-mail: k.l.cooper@sheffield.ac.uk

Conflict of Interest: No conflicts of interest occurred for any author.

Funding

This work was funded by the UK National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme, project number 13-12.

References

- Althof SE, McMahon CG, Waldinger MD, Serefoglu EC, Shindel AW, Adaikan PG, Becher E, Dean J, Giuliano F, Hellstrom WJ, Giraldo A, Glina S, Incrocci L, Jannini E, McCabe M, Parish S, Rowland D, Segraves RT, Sharlip I, Torres LO. An update of the International Society of Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation (PE). *J Sex Med* 2014;11:1392–422.
- Laumann EO, Nicolosi A, Glasser DB, Paik A, Gingell C, Moreira ED, Wang T; GSSAB Investigators' Group. Sexual problems among women and men aged 40–80 y: Prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. *Int J Impot Res* 2005;17:39–57.
- Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: Prevalence and predictors. *J Am Med Assoc* 1999;281:537–44.
- Porst H, Montorsi F, Rosen RC, Gaynor L, Grupe S, Alexander J. The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: Prevalence, comorbidities, and professional help-seeking. *Eur Urol* 2013;51:816–23.
- Rowland DL, Patrick DL, Rothman M, Gagnon DD. The psychological burden of premature ejaculation. *J Urol* 2007;177:1065–70.
- Byers ES, Grenier G. Premature or rapid ejaculation: Heterosexual couples' perceptions of men's ejaculatory behavior. *Arch Sex Behav* 2003;32:261–70.
- Richardson D, Goldmeier D, Green J, Lamba H, Harris JRW. Recommendations for the management of premature ejaculation: BASHH Special Interest Group for Sexual Dysfunction. *Int J STD AIDS* 2006;17:1–6.
- Wespes E, Eardley I, Giuliano F, Hatzichristou D, Hatzimouratidis K, Moncada I, Salonia A, Vardi Y. Guidelines on male sexual dysfunction: Erectile dysfunction and premature ejaculation. Arnhem, the Netherlands: European Association of Urology; 2013.
- Melnik T, Althof S, Atallah AN, Puga MEDS, Glina S, Riera R. Psychosocial interventions for premature ejaculation. *Cochrane Database Syst Rev* 2011;(8):CD008195.
- McMahon CG, Abdo C, Incrocci L, Perelman M, Rowland D, Waldinger M, et al. Disorders of orgasm and ejaculation in men. *J Sex Med* 2004;1:58–65.
- Pastore AL, Pallechi G, Leto A, Pacini L, Iori F, Leonardo C, et al. A prospective randomized study to compare pelvic floor rehabilitation and dapoxetine for treatment of lifelong premature ejaculation. *Int J Androl* 2012;35:528–33.
- Cooper K, Martyn-St James M, Kaltenthaler E, Dickinson K, Cantrell A. Interventions to treat premature ejaculation. *Health Technol Assess* 2013;19.
- Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014.
- Higgins JPT, Altman DG, Sterne JAC, the Cochrane Bias Methods Group, on behalf of the Cochrane Statistical Methods Group. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. *Cochrane handbook for systematic reviews of interventions* version 5.1.0 (updated March 2011). The Cochrane Collaboration; 2011. Available at: <http://www.cochrane-handbook.org> (accessed February 5, 2015).
- de Carufel F, Trudel G. Effects of a new functional-sexological treatment for premature ejaculation. *J Sex Marital Ther* 2006;32:97–114.
- Jern P. Evaluation of a behavioral treatment intervention for premature ejaculation using a handheld stimulating device. *J Sex Marital Ther* 2014;40:358–66.
- Trudel G, Proulx S. Treatment of premature ejaculation by bibliotherapy: An experimental study. *Sex Marital Ther* 1987;2:163–7.
- van Lankveld JJDM, Leusink P, van Diest S, Gijs L, Slob AK. Internet-based brief sex therapy for heterosexual men with sexual dysfunctions: A randomized controlled pilot trial. *J Sex Med* 2009;6:2224–36.
- Li P, Zhu GS, Xu P, Sun LH, Wang P. Interventional effect of behaviour psychotherapy on patients with premature ejaculation. *Zhonghua Nan Ke Xue* 2006;12:717–9.
- Shao X, Li J. [Clinical study on treatment of premature ejaculation with Paroxetine and behavior-therapy]. *Nan Xing Xue Za Zhi* 2008;22:18–20.
- Yuan P, Dai J, Yang Y, Guo J, Liang R. [A comparative study on treatment for premature ejaculation: Citalopram used in combination with behavioral therapy versus either Citalopram or behavioral therapy alone]. *Nan Xing Xue Za Zhi* 2008; 22:35–8.
- Abdel-Hamid IA, El Naggar EA, El Gilany AH. Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation. *Int J Impot Res* 2001;13: 41–5.
- Oguzhanoglu NK, Ozdel O, Aybek Z. The efficacy of fluoxetine and a stop-start technique in the treatment of premature ejaculation and anxiety. *J Clin Psychopharmacol* 2005;25:192–4.
- Eassa BI, El-Shazly MA. Safety and efficacy of tramadol hydrochloride on treatment of premature ejaculation. *Asian J Androl* 2013;15:138–42.

Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher's website:

Appendix S1 Medline search strategy (August 2014).